Skip to main content

Evelo Biosciences, Inc. (EVLO)

NASDAQ: EVLO · IEX Real-Time Price · USD
8.28 -0.06 (-0.72%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap442.14M
Revenue (ttm)n/a
Net Income (ttm)-109.77M
Shares Out53.38M
EPS (ttm)-2.22
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume320,653
Open8.37
Previous Close8.34
Day's Range8.15 - 8.58
52-Week Range3.82 - 19.93
Beta1.49
AnalystsBuy
Price Target22.00 (+165.7%)
Est. Earnings DateOct 28, 2021

About EVLO

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an...

IndustryBiotechnology
IPO DateMay 9, 2018
Employees90
Stock ExchangeNASDAQ
Ticker SymbolEVLO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for EVLO stock is "Buy." The 12-month stock price forecast is 22.00, which is an increase of 165.70% from the latest price.

Price Target
$22.00
(165.70% upside)
Analyst Consensus: Buy

News

Evelo Biosciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treat...

13 hours ago - GlobeNewsWire

Wall Street Analysts Believe Evelo Biosciences, Inc. (EVLO) Could Rally 164%: Here's is How to Trade

The consensus price target hints at a 164.5% upside potential for Evelo Biosciences, Inc. (EVLO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear...

1 week ago - Zacks Investment Research

Evelo Biosciences Presents Preclinical Data for EDP1867 at 37th Congress of the European Committee for Treatment and ...

–Data suggest SINTAX™ medicine may overcome blood-brain barrier limitations to anti-inflammatory drug delivery– –EDP1867 reduced disease severity and incidence of relapse in murine model of multiple scl...

1 week ago - GlobeNewsWire

Evelo (EVLO) Posts Positive Data from Phase II Psoriasis Study

Evelo Biosciences (EVLO) reports encouraging data from a phase II study evaluating EDP1815 for the treatment of mild and moderate psoriasis. Shares up in pre-market trading.

3 weeks ago - Zacks Investment Research

Evelo Biosciences Psoriasis Candidate Shows Benefit In Mid-Stage Study

Evelo Biosciences Inc (NASDAQ: EVLO) has announced data from its Phase 2 study of EDP1815 for mild and moderate psoriasis.  A statistically significant reduction in the Psoriasis Area and Severity Index...

3 weeks ago - Benzinga

Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the...

–Clinically and statistically significant improvement in PASI-50 score achieved––EDP1815 safety and tolerability data comparable to placebo in study––EDP1815 advancing towards registration studies in ps...

3 weeks ago - GlobeNewsWire

Implied Volatility Surging for Evelo Biosciences (EVLO) Stock Options

Investors need to pay close attention to Evelo Biosciences (EVLO) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Evelo Biosciences Appoints Iain McInnes, M.B.Ch.B, Ph.D, to Board of Directors

CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announce...

1 month ago - GlobeNewsWire

Are Options Traders Betting on a Big Move in Evelo (EVLO) Stock?

Investors need to pay close attention to Evelo (EVLO) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Evelo Biosciences Reports Second Quarter 2021 Financial Results and Business Highlights

–EDP1815 Phase 2b data in psoriasis expected in 3Q 2021––Finalized design of Phase 2 clinical trial of EDP1815 in atopic dermatitis; start of trial anticipated in 3Q 2021––Strengthened leadership team w...

2 months ago - GlobeNewsWire

Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that ...

2 months ago - GlobeNewsWire

Evelo Biosciences Announces Grant of Inducement Award

CAMBRIDGE, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that...

3 months ago - GlobeNewsWire

Evelo Biosciences Announces Inducement Award Plan for Expanding Leadership Team

CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that...

4 months ago - GlobeNewsWire

Evelo Biosciences Announces Appointment of Mark Plinio as Chief Commercial Officer

CAMBRIDGE, Mass., June 01, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced...

4 months ago - GlobeNewsWire

Evelo Biosciences to Present at Upcoming Investor Conferences in June

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that m...

4 months ago - GlobeNewsWire

Evelo Biosciences Presents New Preclinical Data for Extracellular Vesicle Anti-inflammatory Product Candidate EDP2939...

–On-track to initiate clinical development of EDP2939 in 2022–

5 months ago - GlobeNewsWire

Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights

–Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting––Strengthened leadership team with appointments of Luca Scavo as Chief Fina...

5 months ago - GlobeNewsWire

Evelo Biosciences Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815 in Atopic Dermatitis

–Evelo presents late-breaking abstract at the International Society of Atopic Dermatitis Annual Meeting–

6 months ago - GlobeNewsWire

Why Ikena Oncology, Evelo Biosciences And 180 Life Sciences Are Rallying Today

Ikena Oncology, Inc. (NASDAQ: IKNA), 180 Life Sciences Corp. (NASDAQ: ATNF) and Evelo Biosciences, Inc. (NASDAQ: EVLO) are among the major biopharma movers of Monday. Ikena Oncology Gains On Fund Buying...

Other symbols:IKNAATNF
6 months ago - Benzinga

Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that...

6 months ago - GlobeNewsWire

Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commercialize Novel Thera...

-- Collaboration expected to accelerate access to Evelo's lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 - if approved by relevant health authorities - to people in select...

6 months ago - GlobeNewsWire

Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

–Announced new positive data in human experimental model of inflammation of EDP1815––Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expec...

7 months ago - GlobeNewsWire

Evelo Biosciences to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that...

7 months ago - GlobeNewsWire

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at th...

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

7 months ago - PRNewsWire

Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Some insiders have been taking advantage of secondary offerings recently.

8 months ago - Benzinga